-
41.发明授权公开(公告)号：US11708347B2
公开(公告)日：2023-07-25
申请号：US17168574
申请日：2021-02-05
发明人： Pravin L. Kotian , Yarlagadda S. Babu , Weihe Zhang , Peng-Cheng Lu , Minwan Wu , Wei Lv , Trung Xuan Nguyen , Zhao Dang , Venkat R. Chintareddy , V. Satish Kumar , Krishnan Raman
IPC分类号： C07D401/10 , C07D209/12 , C07D261/20 , C07D307/80 , C07D333/64 , C07D401/12 , C07D405/10
CPC分类号： C07D401/10 , C07D209/12 , C07D261/20 , C07D307/80 , C07D333/64 , C07D401/12 , C07D405/10
摘要： Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
-
公开(公告)号：US11708333B2
公开(公告)日：2023-07-25
申请号：US17543929
申请日：2021-12-07
发明人： Pravin L. Kotian , Yarlagadda S. Babu , Minwan Wu , Venkat R. Chintareddy , V. Satish Kumar , Weihe Zhang
IPC分类号： C07D231/14 , C07D403/12 , C07D401/14 , C07D401/04 , C07D401/12 , C07D403/04 , C07D405/12 , C07D413/04 , C07D413/12 , C07D417/12
CPC分类号： C07D231/14 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/12 , C07D413/04 , C07D413/12 , C07D417/12
摘要： Disclosed are compounds of formula I:
as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.-
公开(公告)号：US11618731B2
公开(公告)日：2023-04-04
申请号：US16987721
申请日：2020-08-07
发明人： Pravin L. Kotian , Yarlagadda S. Babu , V. Satish Kumar , Venkat R. Chintareddy , Weihe Zhang , Lakshminarayana Vogeti
IPC分类号： C07D213/81 , C07D401/12 , C07D405/12 , C07D413/12 , C07D495/04
摘要： Disclosed are compounds of formula I, II, and III, and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein. Also provided are pharmaceutical compositions comprising such a compound, and methods involving use of the compounds and compositions in the treatment and prevention of acquired or hereditary angioedema, or other diseases and conditions characterized by aberrant kallikrein activity.
-
公开(公告)号：US20220098151A1
公开(公告)日：2022-03-31
申请号：US17374335
申请日：2021-07-13
IPC分类号： C07D207/16 , C07D401/14 , C07D401/12 , C07D409/14 , C07D207/24 , A61P7/00 , A61P17/10 , A61P17/00
摘要： Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
-
公开(公告)号：US11203574B2
公开(公告)日：2021-12-21
申请号：US16828763
申请日：2020-03-24
发明人： Pravin L. Kotian , Yarlagadda S. Babu , Minwan Wu , Venkat R. Chintareddy , V. Satish Kumar , Weihe Zhang
IPC分类号： C07D231/14 , C07D403/12 , C07D401/14 , C07D401/04 , C07D401/12 , C07D403/04 , C07D405/12 , C07D413/04 , C07D413/12 , C07D417/12
摘要： Disclosed are compounds of formula I as described herein, and pharmaceutically acceptable salts thereof. The compounds are disclosed to be inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
-
公开(公告)号：US11192861B2
公开(公告)日：2021-12-07
申请号：US16828755
申请日：2020-03-24
发明人： Pravin L. Kotian , Yarlagadda S. Babu , Minwan Wu , Venkat R. Chintareddy , V. Satish Kumar , Weihe Zhang
IPC分类号： C07D231/14 , C07D403/12 , C07D401/14 , C07D401/04 , C07D401/12 , C07D403/04 , C07D405/12 , C07D413/04 , C07D413/12 , C07D417/12
摘要： Disclosed are compounds of formula I as described herein, and pharmaceutically acceptable salts thereof. The compounds are disclosed to be inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
-
公开(公告)号：US20210260035A1
公开(公告)日：2021-08-26
申请号：US17003552
申请日：2020-08-26
发明人： Pravin L. Kotian , Yarlagadda S. Babu , Weihe Zhang , Lakshminarayana Vogeti , Minwan Wu , Venkat R. Chintareddy , Krishnan Raman
IPC分类号： A61K31/416 , C07D231/56 , C07D403/04 , C07D209/42 , C07D209/12 , C07D403/06 , C07D403/12 , C07D401/06 , C07D487/04 , C07D209/48 , C07D209/40 , C07D401/04 , C07D401/14 , C07D471/04 , C07D401/12 , C07D405/12 , A61P13/10 , A61P21/04 , A61P25/28 , A61P9/00 , A61P37/06 , A61P13/00
摘要： Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising a compound of formula I, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by aberrant complement system activity.
-
公开(公告)号：US20210198204A1
公开(公告)日：2021-07-01
申请号：US16987721
申请日：2020-08-07
发明人： Pravin L. Kotian , Yarlagadda S. Babu , V. Satish Kumar , Venkat R. Chintareddy , Weihe Zhang , Lakshminarayana Vogeti
IPC分类号： C07D213/81 , C07D401/12 , C07D405/12 , C07D413/12 , C07D495/04
摘要： Disclosed are compounds of formula I, II, and III, and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein. Also provided are pharmaceutical compositions comprising such a compound, and methods involving use of the compounds and compositions in the treatment and prevention of acquired or hereditary angioedema, or other diseases and conditions characterized by aberrant kallikrein activity.
-
公开(公告)号：US20210078952A1
公开(公告)日：2021-03-18
申请号：US16845833
申请日：2020-04-10
发明人： Pravin L. Kotian , Yarlagadda S. Babu , Minwan Wu , Venkat R. Chintareddy , V. Satish Kumar , Weihe Zhang
IPC分类号： C07D231/14 , C07D403/12 , C07D401/14 , C07D401/04 , C07D401/12 , C07D403/04 , C07D405/12 , C07D413/04 , C07D413/12 , C07D417/12
摘要： Disclosed are compounds of formula I: as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
-
公开(公告)号：US20190382344A1
公开(公告)日：2019-12-19
申请号：US16345503
申请日：2017-10-27
发明人： Pravin L. Kotian , Yarlagadda S. Babu , V. Satish Kumar , Venkat R. Chintareddy , Weihe Zhang , Lakshminarayana Vogeti
IPC分类号： C07D213/81 , C07D413/12 , C07D405/12 , C07D401/12 , C07D495/04
摘要： Disclosed are compounds of formula I, II, and III, and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein. Also provided are pharmaceutical compositions comprising such a compound, and methods involving use of the compounds and compositions in the treatment and prevention of acquired or hereditary angioedema, or other diseases and conditions characterized by aberrant kallikrein activity.
-
-
-
-
-
-
-
-
-
搜索结果
52 条记录 (耗时 0.031 秒)
